|
| 37460757 | Author Correction: High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial. | Nat Med | 2024 |
| 37963304 | Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in <i>BRCA1</i> and/or <i>BRCA2</i> in the PROfound Trial. | J Clin Oncol | 2024 |
| 37882463 | Therapeutic biomarkers in metastatic castration-resistant prostate cancer: does the state matter? | Crit Rev Clin Lab Sci | 2024 |
| 37673768 | Early On-treatment Circulating Tumor DNA Measurements and Response to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer. | Eur Urol Oncol | 2024 |
| 36224377 | Incidence and survival of castration-resistant prostate cancer patients with visceral metastases: results from the Dutch CAPRI-registry. | Prostate Cancer Prostatic Dis | 2023 |
| 37714168 | Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. | Lancet Oncol | 2023 |
| 38072760 | Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer. | Eur Urol Oncol | 2023 |
| 38061007 | Liquid Biopsies for Early Response Evaluation of Radium-223 in Metastatic Prostate Cancer. | JCO Precis Oncol | 2023 |
| 37689306 | PARPing up the right tree; an overview of PARP inhibitors for metastatic castration-resistant prostate cancer. | Cancer Lett | 2023 |
| 37643855 | TripleAiM1: a nationwide registry of de novo metastatic hormone-sensitive prostate cancer with prospective quality-of-life assessment. | BMJ Open | 2023 |
| 37536738 | <sup>68</sup>Ga-PSMA PET/CT for Response Evaluation of <sup>223</sup>Ra Treatment in Metastatic Prostate Cancer. | J Nucl Med | 2023 |
| 35804188 | Health-related quality of life, psychological distress, and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 therapy. | Prostate Cancer Prostatic Dis | 2023 |
| 35771253 | Intratumoral T cell depletion following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer is associated with poor clinical outcome. | Cancer Immunol Immunother | 2023 |
| 35750582 | Patient-reported Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Harboring DNA Damage Response Alterations Treated with Talazoparib: Results from TALAPRO-1. | Eur Urol | 2023 |
| 37458966 | Clinical Pharmacokinetics and Pharmacodynamics of the Next Generation Androgen Receptor Inhibitor-Darolutamide. | Clin Pharmacokinet | 2023 |
| 37290035 | Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial. | J Clin Oncol | 2023 |
| 37345149 | Cross-Resistance between Platinum-Based Chemotherapy and PARP Inhibitors in Castration-Resistant Prostate Cancer. | Cancers (Basel) | 2023 |
| 37240349 | Transcriptome Profiling of Circulating Tumor Cells to Predict Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer. | Int J Mol Sci | 2023 |
| 37003085 | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. | Eur J Cancer | 2023 |
| 37164814 | Tumoral Ki67 and PSMA Expression in Fresh Pre-PSMA-RLT Biopsies and Its Relation With PSMA-PET Imaging and Outcomes of PSMA-RLT in Patients With mCRPC. | Clin Genitourin Cancer | 2023 |
| 37095077 | In silico cancer immunotherapy trials uncover the consequences of therapy-specific response patterns for clinical trial design and outcome. | Nat Commun | 2023 |
| 36996325 | Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer. | Clin Cancer Res | 2023 |
| 36813980 | Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies. | Eur J Nucl Med Mol Imaging | 2023 |
| 36692682 | Optimization of the radiation dosimetry protocol in Lutetium-177-PSMA therapy: toward clinical implementation. | EJNMMI Res | 2023 |
| 36874601 | Genetic Aspects and Molecular Testing in Prostate Cancer: A Report from a Dutch Multidisciplinary Consensus Meeting. | Eur Urol Open Sci | 2023 |
| 36732628 | High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial. | Nat Med | 2023 |
| 36494221 | Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. | Eur Urol | 2023 |
| 34135475 | Reovirus mutant jin-3 exhibits lytic and immune-stimulatory effects in preclinical human prostate cancer models. | Cancer Gene Ther | 2022 |
| 35800157 | Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtype. | Oncoimmunology | 2022 |
| 35598359 | Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study. | Eur J Cancer | 2022 |
| 36548180 | The Androgen Regulated lncRNA <i>NAALADL2-AS2</i> Promotes Tumor Cell Survival in Prostate Cancer. | Noncoding RNA | 2022 |
| 36612293 | PSMA-RLT in Patients with Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Study. | Cancers (Basel) | 2022 |
| 36124924 | Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses. | Oncologist | 2022 |
| 36055228 | Detection and localization of early- and late-stage cancers using platelet RNA. | Cancer Cell | 2022 |
| 35046958 | Spatial and Temporal Heterogeneity of Tumor-Infiltrating Lymphocytes in Advanced Urothelial Cancer. | Front Immunol | 2022 |
| 35314962 | Being Transparent About Brilliant Failures: An Attempt to Use Real-World Data in a Disease Model for Patients with Castration-Resistant Prostate Cancer. | Drugs Real World Outcomes | 2022 |
| 34912074 | Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer. | Br J Cancer | 2022 |
| 35039230 | Evidence or Prejudice? Critical Re-Analysis of Randomized Controlled Trials Comparing Overall Survival After Cisplatin Versus Carboplatin-Based Regimens in Advanced Urothelial Carcinoma. | Clin Genitourin Cancer | 2022 |
| 35091440 | Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib). | Clin Cancer Res | 2022 |
| 35210590 | Correction to: Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer. | Br J Cancer | 2022 |
| 35086719 | Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma. | Eur Urol | 2022 |
| 34436788 | The effect of chemotherapy on the exposure-response relation of abiraterone in metastatic castration-resistant prostate cancer. | Br J Clin Pharmacol | 2022 |
| 34848157 | Symptomatic Skeletal Events and the Use of Bone Health Agents in a Real-World Treated Metastatic Castration Resistant Prostate Cancer Population: Results From the CAPRI-Study in the Netherlands. | Clin Genitourin Cancer | 2022 |
| 34623453 | [<sup>68</sup>Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [<sup>177</sup>Lu]Lu-PSMA-617 treatment. | Eur J Nucl Med Mol Imaging | 2022 |
| 34535437 | Overall Survival of Patients Receiving Cisplatin or Carboplatin for Primary Metastatic Urothelial Carcinoma of the Bladder: A Contemporary Dutch Nationwide Cohort Study. | Eur Urol Focus | 2022 |
| 34741789 | Prognostic importance of concomitant non-regional lymph node and bone metastases in men with newly diagnosed metastatic prostate cancer. | BJU Int | 2022 |
| 34218300 | Intra-therapeutic dosimetry of [<sup>177</sup>Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome. | Eur J Nucl Med Mol Imaging | 2022 |
| 34253846 | Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer. | Prostate Cancer Prostatic Dis | 2022 |
| 31601523 | Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer: Results from the Dutch Castration-resistant Prostate Cancer Registry. | Eur Urol Oncol | 2021 |
| 35475128 | M1a prostate cancer: Results of a Dutch multidisciplinary consensus meeting. | BJUI Compass | 2021 |